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Objectives: The aim of our study is to calculate the annual health insurance 
treatment cost of anxiety in Hungary. MethOds: The data derive from the finan-
cial database of the Hungarian National Health Insurance Fund Administration 
(NHIFA), the only health care financing agency in Hungary. We analyzed the 
health insurance treatment cost and the number of patients for the year 2010. 
The following cost categories were included into the study: out-patient care, in-
patient care, CT-MRI, PET, home care, transportation, general practitioner, drugs 
and medical devices. Results: The Hungarian National Health Insurance Fund 
Administration spent 13.535 billion Hungarian Forint (HUF) (65.026 million USD) 
for the treatment of anxiety patients. The annual average expenditure per patient 
was 13323 HUF (64 USD) while the average expenditure per one inhabitant was 1352 
HUF (6.5 USD). Major cost drivers were general practitioners of primary care (43.8 
% of total health insurance costs), pharmaceuticals (32.2 %) and outpatient care 
(12.4 %). The number of patients with anxiety disease was 1014 per 100000 popula-
tions. We found the highest patient number in general practitioners of primary care 
(1015938 patients), pharmaceuticals (774096 patients) and outpatient care (521760 
patients). cOnclusiOns: Anxiety represents a significant burden for the health 
insurance system. General practitioners of primary care and pharmaceutical reim-
bursement are the major cost drivers for anxiety disease in Hungary.
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Objectives: Resulting from the scarcity of literature on dementia in China, a 
Delphi panel was used to obtain information on disease management, resource 
utilisation and associated costs for patients with moderate or severe dementia in 
China. The panel results were used as input data for a health economic model com-
paring different alternative strategies for treatment of dementia. MethOds: The 
Delphi panel method was used to leverage expertise of physicians involved in the 
treatment of dementia (Round-1 interviews with eight interviewees) and hospital 
administrators (Round-2 interviews with two interviewees). Final Delphi meeting 
gathered six experts from previous interviewees to reach a consensus. Round-1 
interviews collected information of establishing a diagnosis for dementia, dementia 
disease management and the distribution of patients by severity, dependence and 
aggressiveness. Round-2 interviews were based on results of Round-1 interviews 
to collect data on relevant costs. Interviews were done individually without shar-
ing information from other interviewees. Results from two rounds were integrated 
and shared in the final Delphi discussion. A consensus was reached to obtain the 
final value or range of values of interest. Results: Distribution of independent/
non-aggressive, independent/aggressive, dependent/non-aggressive, and depend-
ent/aggressive moderate dementia patients was 70%, 15%, 10% and 5% at time 
of first diagnosis . Unit costs and resources utilisation, collected for each health 
state for a cycle of 6-months, showed that severe dependent/aggressive dementia 
patients required the most time from caregivers (15 hours/day). Moderate depend-
ent/aggressive patients had the highest probability (90%) to be hospitalised. The 
average stay of hospitalisation was two months. Moderate and severe patients had 
the same probability of nursing home utilisation (0%, 20%, 80% and 20% for each 
health state). cOnclusiOns: Delphi panel may be a useful approach to collect 
data for diseases when they are not published in the literature or when automated 
health care databases are not available or accessible.
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Objectives: To review studies that investigated the costs and resource use of 
managing major depressive disorder (MDD) in China. MethOds: A structured 
literature review on published articles in both English and Mandarin languages 
was conducted. Literature search was conducted using PubMed, Cochrane, Wan 
Fang, and VIP databases. Articles published between 2000 to 2013 were selected. The 
inclusion criteria included studies conducted in China, and studies that reported 
direct and indirect costs in MDD management, including factors that affected these 
costs, as well as resources used in managing MDD. Four reviewers (two for each 
language) independently selected and reviewed the articles. Direct cost included 
costs of MDD treatment (e.g. medication, investigation, hospitalisation, nursing 
care…etc.); whereas indirect costs included caregiver cost, productivity loss, and 
mortality (suicide). Results: A total of 24 articles in Mandarin and English were 
selected and reviewed. Based on the review, direct cost for MDD reported ranged 
from RMB 1,000 to RMB 6,000, whereas indirect cost reported ranged from RMB 
2,000 to RMB 51,000. Loss of productivity, when evaluated, accounted for more than 
75% of indirect costs. Serotonin norepinephrine reuptake inhibitor (SNRI) incurred 
the highest direct medical cost compared to selective serotonin reuptake inhibitor 
(SSRI), followed by tricyclic antidepressants (TCA). The treatment costs for MDD 
had increased gradually over the years. Some of the common factors affecting the 
cost of MDD management included treatment duration, payment methods, types 
of drug prescribed, comorbidity, disease severity and marital status. Studies had 
shown that most patients first seek treatment in general clinic or hospitals (76%) 
consisted of the direct economic burden of this disease. cOnclusiOns: Serious 
economic burden has been caused by schizophrenia and increased sharply in China. 
Indirect cost of schizophrenia is largely more than its direct cost.
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Objectives: Ziprasidone is increasingly used for the treatment of schizophrenia 
and bipolar disorder. The purpose of this study is to compare health care costs 
and utilization associated with use of ziprasidone and olanzapine. MethOds: 
Schizophrenia and bipolar disorder patients who initiated use of ziprasidone or 
olanzapine between 01/2007 and 12/2010 were identified in the IMS LifeLink™ 
Health Plan Claims Database. Claims were summarized into treatment episodes, 
and one-year costs and utilization after the initiation of episodes were analyzed. 
OLS regressions, general liner models, and two-part models were used to com-
pare various types of costs associated with the use of ziprasidone and olanzapine. 
Logistic regressions, Poisson regressions, and Hurdle models were used to com-
pare the numbers of emergency room visits and hospitalizations associated with 
each drug. Lastly, we used various statistical methods to test the sensitivity of our 
estimates. Results: We identified 7,138 (46.93%) ziprasidone episodes and 8,072 
(53.07%) olanzapine episodes, and found that patients using ziprasidone were signif-
icantly younger (41.50 vs. 45.38) and were significantly less likely to be male (29.81% 
vs. 44.21%). At baseline, ziprasidone group and olanzapine group differed in total 
costs and several other components of costs. Benchmark analyses show that use of 
ziprasidone, when compared to olanzapine, was associated with significantly higher 
medication costs ($232, p< 0.01) and outpatient costs ($501, p< 0.05), but decreased 
ER costs (-$73, p< 0.05). Ziprasidone was also associated with significantly fewer 
ER visits (0.266, p< 0.001) and hospitalizations (1.117, p< 0.001). Sensitivity analyses 
suggest these results were robust. cOnclusiOns: While ziprasidone is associated 
with higher medication costs and outpatient costs, it reduces patients’ utilization 
of ER and inpatient services.
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Objectives: The aim of our study is to calculate the annual health insurance 
treatment cost of Alzheimer dementia disease in Hungary. MethOds: The data 
derive from the financial database of the Hungarian National Health Insurance 
Fund Administration (NHIFA), the only health care financing agency in Hungary. We 
analyzed the health insurance treatment cost and the number of patients for the 
year 2010. The following cost categories were included into the study: out-patient 
care, in-patient care, CT-MRI, PET, home care, transportation, general practitioner, 
drugs and medical devices. Results: The Hungarian National Health Insurance 
Fund Administration spent 4.426 billion Hungarian Forint (HUF) (21.266 million 
USD) for the treatment of Alzheimer patients. The annual average expenditure per 
patient was 72881 HUF (350 USD) while the average expenditure per one inhab-
itant was 442 HUF (2.1 USD). Major cost drivers were acute inpatient care (45.8 
% of total health insurance costs), chronic inpatient care (28.1 %) and pharma-
ceuticals (10.4 %). The number of patients with Alzheimer disease was 60.6 per 
100000 populations. We found the highest patient number in outpatient care budget 
(60735 patients), general practitioners (60234 patients) and pharmaceuticals (37724 
patients). cOnclusiOns: Alzheimer dementia disease represents a significant bur-
den for the health insurance system. Hospital care (both acute and chronic) is the 
major cost driver for Alzheimer disease in Hungary.
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Objectives: To study the treatment pattern and cost of illness in bipolar disorder 
patients in tertiary care hospital in South India. MethOds: A retrospective study 
was conducted in a tertiary care teaching hospital of South India. Data were col-
lected retrospectively from medical record section from 2012 to 2013 in suitable 
designed case record form. Data were analysed by using SPSS 20.0. Results: Total 
of 100 cases of bipolar disorder was followed during the study period. Among them 
66 were males and 34 were females. The mean age of the study population was 
found to be 46.2+13.3 years. Among the social history 13 people were alcoholic and 
60% of the study population had a family history of known psychiatric disorder. 
The mean duration of illness of the study population was found to be21.8+9.8years. 
Among the study population 34 patients were diagnosed with mania and 46 patients 
diagnosed with depression. Mood examination revealed that 38 patients were happy 
followed by 22 patients were irritable. Affective examinations showed maximum 
were euphoric. Insight examination showed Grade 1 predominance. The different 
treatment pattern revealed that all of them were prescribed with mood stabilizer 
followed by anti-psychotic (93) and hypnotics (86). The average hospitalization cost 
of the patient was found to be 7477.83 + 5989.67 Rupees with median hospital stay 
of 7(5) days. The average treatment cost constitutes total 50% of the hospitalization 
cost. cOnclusiOns: Mood stabilizers and anti-psychotics were the main treatment 
strategies among the bipolar patients and drug cost consumes 50% of the total cost 
of hospitalization. Pharmacoeconomic studies plays important role in estimating 
the total health care burden in bipolar disorders.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A769
more than one worker over four will spend one hour per day providing care to a 
patient with dementia. Increasing the proportion of treated patients may be a way 
to control costs and reduce burden on the society.
Mental HealtH – Patient-reported outcomes & Patient Preference studies
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Objectives: The aim of this study was to explore patients’ adherence to antidepres-
sant medication and predictors are associated with adherence, among patients diag-
nosed with depression in a psychiatric hospital in Riyadh , Saudi Arabia. MethOds: 
Non experimental cross-sectional design used to measure adherence to antide-
pressants among depressed patients and predictors are associated with adher-
ence, patients were recruit from outpatient clinic at AL-Amal hospital in Riyadh 
(psychiatric hospital) between August 2013 and January 2014. Results: A total of 
403 patients meet the inclusion criteria and were participated in this study. Two 
hundred three representing 50.37 % of the total study sample, were female, while the 
remaining 200 (49.6 %) were male, with average 39 years. 52.9% of the patients report 
low adherence to antidepressant medication with a statically significant different 
between low adherence and high adherence scour in female gender, younger age, 
patients with shorter duration of illness and have lees number of visit to outpa-
tient clinic. cOnclusiOns: Low adherence is a common health problem among 
depressed patients in Saudi Arabia, this study has improve understanding of adher-
ence predictors to antidepressant and their association, this understanding should 
help care giver and stakeholder to improve depressed patient management and 
clinical outcome by addressing medications taking behavior using a systematic 
approach based in this finding.
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Objectives: The aim of this study was to explore patients’ general and specific 
beliefs about medicines among depressed patients and effect on adherence and 
other clinical outcome in Saudi Arabia. MethOds: A cross-sectional design used 
to measure patients’ general and specific beliefs among depressed patients, using 
BMQ general and specific scales. Patients were recruit from outpatient clinic at 
AL-Amal hospital in Riyadh (psychiatric hospital). Results: A total of 403 patients 
meet the inclusion criteria and were participated in this study. Two hundred three 
representing 50.37 % of the total study sample, were female, while the remaining 
200 (49.6 %) were male, with average 39 years. 52.9% of patients report low adherence 
to antidepressant medication. Both low and high adherence group scored high in 
the necessity beliefs (18.02 (SD 3.91)-18.32 (SD3.9)respectively with no statistically 
different. contrariwise patients with high adherence had significantly lower level of 
concerns belief about antidepressants medication and less harmful belief also the 
same finding with general overuse belief. cOnclusiOns: General patients beliefs 
either general overuse or general harm about medication influence patients taking 
medication behavior and have negative correlation with adherence to medication on 
other hand only specific concerns belief to antidepressant have a positive correla-
tion with adherence to antidepressant this finding will help psychiatric to improve 
adherence and clinical outcome by addressing medications taking behavior using 
a systematic approach based in this finding.
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Nwokeji E.D.1, Rascati K.L.2, Nemeth W.C.3, Jordan K.D.3, Novak S.1
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Objectives: The objective of this pilot study was to examine opioid analgesic (OA) 
use and patient reported outcomes (PRO) among opioid-dependent chronic nonma-
lignant pain (CNMP) patients placed on buprenorphine therapy in the Functional 
Restoration and Pain Management (FRPM) program. MethOds: A retrospective 
cohort analysis of administrative claims, medical records and responses to PRO 
questionnaires was conducted among Texas Workers Compensation (TWC) benefi-
ciaries enrolled in the FRPM program. Prescription utilization patterns, pain sever-
ity and self-report PROs were assessed during a 3-month observation period. PRO 
measures included the Visual Analogue Scale (VAS) for pain assessment, McGill Pain 
Questionnaire (MPQ), Beck Anxiety Inventory (BAI), and Beck Depression Inventory-II 
(BDI-II). Eligible patients were ≥ 18 years of age, opioid dependent, had a history 
of chronic pain medications, receiving buprenorphine therapy, and continuously 
enrolled in TWC benefit during the 3-month period. Results: The mean age of 
eligible study participants (N= 19) was 49.0 years ±7.6. A majority of patients were 
male (58%), white (63%), had a depression comorbidity (79%) and chronic pain lum-
bar diagnosis (47%). Overall, patients enrolled in the study showed a significant 
reduction in OA medication utilization (p< 0.01) at months 1 and 2-3 compared to 
baseline. For the PRO measures, a significant reduction in patient VAS pain scores 
was observed between baseline and month 1 (p= 0.03), no increases in pain scores 
were observed at months 2-3. Significant decreases in MPQ-A (p< 0.04) and BDI-II 
(p< 0.01) scores were observed between baseline and months 1 and 2-3. No dif-
ferences for BAI scores were observed. cOnclusiOns: Though a pilot study, the 
results suggest that opioid dependent patients receiving buprenorphine therapy in 
the FRPM program has the potential of improving health outcomes of patients with 
and only a small percentage of patients (23.7%) was first treated by mental health 
specialists. cOnclusiOns: The reported cost of managing MDD in China was high. 
Most patients first seek treatment in general medical clinics or hospitals instead 
of mental health specialists.
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Objectives: Various pharmacotherapy options are available for major depressive 
disorder (MDD) in China. However, the cost-effectiveness (CE) evaluations for these 
treatments are not systematically reported in English literature. A structured lit-
erature review was conducted to identify the health economics data of available 
treatment options in China. MethOds: A structured literature review on published 
articles in both English and Mandarin languages was conducted. Literature search 
was conducted using PubMed, Cochrane, WAN FANG, and VIP databases. Articles 
published between 2000 and 2013 were selected. The inclusion criteria included 
studies on Chinese population based in China only, as well as studies that reported 
cost effectiveness ratio (CER) or incremental cost effectiveness ratio (ICER) of MDD 
pharmacotherapy. Four reviewers (two for each language) independently selected, 
reviewed and extracted information from the articles. Results: 17 English & 63 
Mandarin articles were identified. None of the English articles and 23 Mandarin arti-
cles fulfilled the inclusion criteria. 17 of the 23 Mandarin articles analysed the CER 
or ICER of the serotonin norepinephrine reuptake inhibitor (SNRI), Venlafaxine com-
pared with other anti-depressants such as selective serotonin reuptake inhibitor 
(SSRI), tricyclic (TCA) or tetracyclic (TeCA) antidepressants. The remaining 6 articles 
analysed the CE of other anti-depressants not involving SNRI. The review showed 
conflicting outcomes due to heterogeneous study methodology. Ten out of 23 arti-
cles reported TCA/TeCA treatment to be most cost-effective treatment whereas six 
articles were in favour of SSRI and four articles favoured SNRI. cOnclusiOns: 
TCA/TeCA had comparable effectiveness compared to SNRI or SSRI. Despite the 
lower treatment cost with TCA/TeCA use, these treatments had higher AE rates 
compared to SNRI or SSRI, which were not taken into account during cost evaluation. 
This review identified several methodological issues and despite the calculation 
of ICER or CER, further studies are required to compare evidence on cost-effective 
anti-depressant treatment.
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econoMIc evaluatIon of alzHeIMer
Bae J.
Chungbuk University, Cheong Ju, South Korea
Objectives: The Alzheimer diseases (AD) steadily increase with age in the early 
population. Considering that all over the world holds the fastest aging popula-
tion. According to the Alzheimer’s Association, cost spending is projected to be 
$2000 billion in 2050. The purpose of this study is to observe the cost effectiveness 
analysis (CEA) for the Alzheimer Drug. MethOds: The report was reviewed through 
report of ministry of welfare in Korea and clinical report data of paper about the 
Alzheimer drug inhibitors which are Aricept, Exelon and Reminyl. This analysis 
was used by CEA. Results: In Korea, the patients increased 84,000 in 2005 and 
262,000 in 2010. The patients increase 3.1 fold more increase. The total medical 
expenses $0.13 billion in 2005 and $0.81 billion in 2010. The total medical expense 
was 6.1 more increase. The per capita cost of treatment of Alzheimer diseases (AD) 
spends about 1.5$ in 2005 and 3.1$ in 2010. The per capita cost of treatment is 2 
times greater. Also,The medical fee of Aricept is $2, Exelon is $1.8 and Reminyl $1.3 
in Korea. The best drug of cost effectiveness is Reminyl and then Aricept. However, 
Exelon rejected within the cost effectiveness analysis, when anyone has a limited 
cost. cOnclusiOns: This revision strived to reduce the per capita cost of treat-
ment of AD. Most of all, it is critical not to delay care in Alzheimer patients in order 
to avoid increased direct medical costs. Therefore, in Alzheimer care, it is most 
critical to adequately check the symptom early discovery through the appropriate 
management techniques.
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Objectives: Elderly dementia results in progressive cognitive impairment and, 
eventually, the inability to living independently. The objective of this study was 
to assess the time required to provide care to patients with dementia according 
to their health state, and the consequences for the active population in China in 
2050. MethOds: The Chinese demographic forecasts for 2050 were put in balance 
with the need of estimated caregiving time needed by the dementia population. 
Demographic data, proportions of diagnosed and/or treated patients were provided 
by the China Alzheimer’s project Memory360. A Markov model was developed to 
estimate the average caregiver’s time needed per patient per day over 5 years, 
separately for treated and not treated patients. Results: The proportion of eco-
nomically active population aged between 15 and 59 in China in 2050 is estimated 
at 50% compared to the currently observed 70%.There will be approximately two 
workers for one elderly. It was found that untreated patient will require around 9.3 
hours per day compared to 6.7 hours per day required by a treated patient. It was 
estimated that there will be 21.6 million patients with dementia in China with only 
21.3% among them receiving treatment. More than 188 million hours per day will be 
needed to take care of Chinese dementia patients for around 690 million working 
people. cOnclusiOns: In the future, the situation in China will be dramatic due to 
the increase in the proportion of elderly and simultaneous reduction by around one 
fourth of the proportion of adults younger than 60. It was estimated that in average 
